

10th July 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

- 1. Does your trust employ one or more homecare medicine services provider(s) to deliver and/or administer medicines to patients in their normal residence? If so, what is the name of the provider(s)?**

Yes, we have patients with 8 different homecare companies, as follows:

Alcura UK Ltd.
Calea UK Ltd.
Fresenius Medical Care (UK) Ltd.
HealthNet Homecare
Lloyds Clinical
Personal Homecare Pharmacy
Pharmaxo Pharmacy Services Ltd
Sciensus

- 2. Please provide a breakdown on spend by each clinical homecare provider for the following NHS financial years: FY24, FY25 and FY26**

Please see the attached document - 'FOI 26-359 Response'.

- 3. For each provider, how many active patients received your homecare medicines service as of 31 March 2024, 31 March 2025 and 31 March 2026?**

Please see the attached document - 'FOI 26-359 Response'.

- 4. For each provider, please provide a list of medications delivered and/or administered through this service as of 31 March 2024, 31 March 2025 and 31 March 2026?**

Please see the attached document - 'FOI 26-359 Response'..

5. For each provider, as a proportion of all deliveries, what percentage of medicine and ancillaries deliveries were late in the most recent reporting period for which you have data, and in two comparable reporting periods (eg if giving data for March 2026, please also give figures for March 2025 and March 2024)? Please state what period the figures are for.

Homecare company	March 2024	March 2025	March 2026
Alcura UK Ltd	We do not hold this information	1.3%	11.3%
Calea UK Ltd	0.0%	0.0%	0.0%
Fresenius Medical Care (UK) Ltd	0.0%	0.0%	0.0%
HealthNet Homecare	13.82%	9.96%	7.9%
Lloyds Clinical	0.4%	1.2%	0.0%
Personal Homecare Pharmacy	0.0%	0.0%	0.25%
Pharmaxo Pharmacy Services Ltd	0.0%	10.0%	0.0%
Sciensus	5.1%	5.1%	5.3%

6. Please provide a breakdown of the expenditure (£m) on each of the top 10 clinical homecare products/drugs dispensed to clinical homecare service users in your Trust for the following NHS financial years: FY24, FY25 and FY26

Whilst the Trust holds the information requested, it is applying a Section 43(2) exemption in relation to this part of the request as the release of the information is likely to prejudice its commercial interests.

In applying the exemption consideration has been given to the public interest in enabling scrutiny of public sector decision making and the general public interest in accountability and transparency.

We have concluded that sharing commercials could disadvantage the incumbent supplier against their competitors. The information could provide competitors with the suppliers pricing, which could result in these suppliers obtaining a competitive advantage which could result in the Trust not obtaining best value for money.

In this instance, we consider that the public interest in withholding the information is greater than the public interest in disclosing the information.

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm

FOI 26/359 - East Sussex Healthcare NHS Trust**FY24**

supplier	TotalSpend
Alcura	£132,172
Fresenius	£33,401
Healthnet	£2,317,259
Lloyds	£924,290
Pharmaxo	£17,358
PHP	£19,692
Sciensus	£3,663,628

FY25

supplier	TotalSpend
Alcura	£671,701
Calea	£242,297
Fresenius	£111,052
Healthnet	£2,301,776
Lloyds	£1,526,193
Pharmaxo	£239,670
PHP	£493,932
Sciensus	£2,506,347

FY26

supplier	TotalSpend
Alcura	£2,445,379
Calea	£320,931
Fresenius	£127,181
Healthnet	£3,414,836
Lloyds	£1,328,343
Pharmaxo	£350,824
PHP	£604,431
Sciensus	£2,436,492

Alcura

April 2023-March 2024		April 2024-March 2025		April 2025-March 2026	
Acalabrutinib	Calquence	Acalabrutinib	Calquence	Abiraterone	Generic
Aciclovir		Aciclovir		Acalabrutinib	Calquence
Apremilast	Otezla	Allopurinol		Aciclovir	
Atovaquone		Apremilast	Otezla	Allopurinol	
Baricitinib	Olumiant	Avacopan	Tavneos	Apalutamide	Erleada
Bosutinib	Bosulif	Bosutinib	Bosulif	Apremilast	Otezla
Chlorphenamine		Bosutinib	Generic	Asciminib	Atovaquone
Co-Trimoxazole		Co-Trimoxazole		Scemblix	
Cyclizine		Cyclizine		Avacopan	Tavneos
Dasatinib	Generic	Dasatinib	Generic	Avatrombopag	Doptelet
Fremanezumab	Ajovy	Filgrastim		Bosutinib	Generic
Ibrutinib	Imbruvica	Fremanezumab	Ajovy	Co-Trimoxazole	
Imatinib	Glivec	Ibrutinib	Imbruvica	Cyclizine	
Loperamide		Imatinib	Glivec	Darolutamide	Nubeqa
Metoclopramide		Loperamide		Dasatinib	Generic
Nilotinib	Tasigna	Methotrexate	Metoject	Deferasirox	
Active Patients	228	Metoclopramide		Enzalutamide	Xtandi
		Nilotinib	Tasigna	Epoetin Zeta	Retacrit
		Ritlecitinib	Litfulo	Folic Acid	
		Ruxolitinib	Jakavi	Fostamatinib	Tavlesse
		Zanubrutinib	Brukinsa	Fremanezumab	Ajovy
		Active Patients	116	Ibrutinib	Imbruvica
				Imatinib	Glivec
				Lamivudine	
				Loperamide	
				Methotrexate	Metoject
				Metoclopramide	
				Midostaurin	Rydapt
				Momelotinib	Omjjara
				Nilotinib	Tasigna
				Ondansetron	
				Palbociclib	Ibrance
				Paracetamol	
				Prednisolone	
				Ribociclib	Kisqali
				Ritlecitinib	Litfulo
				Ruxolitinib	Jakavi
				Zanubrutinib	Brukinsa
				Active Patients	460

Calea

April 2023-March 2024

April 2024-March 2025

April 2025-March 2026

Tocilizumab	Tyenne
Active Patients	65

Tocilizumab	Tyenne
Active Patients	66

Fresenius

April 2023-March 2024		April 2024-March 2025		April 2025-March 2026	
Evolocumab	Repatha	Evolocumab	Repatha	Evolocumab	Repatha
Active Patients	58	Active Patients	56	Active Patients	52

Sciensus

April 2023-March 2024

Abatacept	Orencia
Adalimumab	Humira
Adalimumab	Imraldi
Adalimumab	Amgevita
Apremilast	Otezla
Baricitinib	Olumiant
Certolizumab Pegol	Cimzia
Chlorphenamine	
Dimethyl Fumarate	Tecfidera
Etanercept	Benepali
Etanercept	Enbrel
Galcanezumab	Emgality
Golimumab	Simponi
Guselkumab	Tremfya
Interferon Beta	Avonex
Interferon Beta	Betaferon
Interferon Beta	Rebif
Ixekizumab	Taltz
Lanreotide	Somatuline Autogel
Lanreotide	Lanreotide Ipsen
Methotrexate	Metoject
Omalizumab	Xolair
Peginterferon Beta-1a	Plegridy
Secukinumab	Cosentyx
Somatropin	Genotropin
Somatropin	FlexPro
Somatropin	Omnitrope
Tocilizumab	RoActemra
Tofacitinib Citrate	Xeljanz
Trastuzumab	Herceptin
Ustekinumab	Stelara
Vedolizumab	Entyvio
Active Patients	1390

April 2024-March 2025

Adalimumab	Amgevita
Adalimumab	Humira
Apremilast	Otezla
Baricitinib	Olumiant
Certolizumab Pegol	Cimzia
Chlorphenamine	
Dimethyl Fumarate	Generic
Dimethyl Fumarate	Tecfidera
Etanercept	Benepali
Etanercept	Enbrel
Etanercept	Erelzi
Etrasimod	Velsipity
Golimumab	Simponi
Interferon Beta	Avonex
Interferon Beta	Betaferon
Interferon Beta	Rebif
Ixekizumab	Taltz
Lanreotide	Lanreotide Ipsen
Methotrexate	Metoject
Mirikizumab	Omvo
Peginterferon Beta-1a	Plegridy
Secukinumab	Cosentyx
Somatropin	Genotropin
Somatropin	Omnitrope
Teriflunomide	Generic
Tofacitinib Citrate	Xeljanz
Trastuzumab	Herceptin
Vedolizumab	Entyvio
Active Patients	827

April 2025-March 2026

Adalimumab	Amgevita
Adalimumab	Humira
Apremilast	Otezla
Baricitinib	Olumiant
Certolizumab Pegol	Cimzia
Dimethyl Fumarate	Generic
Etanercept	Benepali
Etanercept	Enbrel
Etanercept	Erelzi
Etrasimod	Velsipity
Golimumab	Gobivaz
Golimumab	Simponi
Interferon Beta	Avonex
Interferon Beta	Betaferon
Interferon Beta	Rebif
Ixekizumab	Taltz
Lanreotide	Lanreotide Ipsen
Lanreotide	Somatuline Autogel
Methotrexate	Metoject
Mirikizumab	Omvo
Peginterferon Beta-1a	Plegridy
Risankizumab	Skyrizi
Ritlecitinib	Litfulo
Secukinumab	Cosentyx
Somatropin	Genotropin
Somatropin	Omnitrope
Somatropin	Norditropin
Teriflunomide	Generic
Tofacitinib Citrate	Xeljanz
Vedolizumab	Entyvio
Active Patients	705

Healthnet

April 2023-March 2024		April 2024-March 2025		April 2025-March 2026	
Adalimumab	Imraldi	Adalimumab	Hyrimoz	Abrocitinib	Cibinqo
Adalimumab	Hyrimoz	Adalimumab	Imraldi	Adalimumab	Imraldi
Adalimumab	Yuflyma	Adalimumab	Yuflyma	Adalimumab	Yuflyma
Alirocumab	Praluent	Alirocumab	Praluent	Alirocumab	Praluent
Brodalumab	Kyntheum	Bimekizumab	Bimzelx	Bimekizumab	Bimzelx
Deucravacitinib	Sotyktu	Brodalumab	Kyntheum	Brodalumab	Kyntheum
Dupilumab	Dupixent	Deucravacitinib	Sotyktu	Deucravacitinib	Sotyktu
Erenumab	Aimovig	Dupilumab	Dupixent	Dupilumab	Dupixent
Filgotinib	Jyseleca	Erenumab	Aimovig	Erenumab	Aimovig
Infliximab	Remsima	Evolocumab	Repatha	Evolocumab	Repatha
Omalizumab	Xolair	Filgotinib	Jyseleca	Filgotinib	Jyseleca
Risankizumab	Skyrizi	Infliximab	Remsima	Galcanzumab	Emgality
Sarilumab	Kevzara	Kyntheum	Brodalumab	Golimumab	Simponi
Teriflunomide	Aubagio	Omalizumab	Xolair	Infliximab	Remsima
Teriparatide	Movymia	Risankizumab	Skyrizi	Omalizumab	Omlyclo
Teriparatide	Sondelbay	Sarilumab	Kevzara	Omalizumab	Xolair
Tralokinumab	Adtralza	Teriflunomide	Aubagio	Risankizumab	Skyrizi
Upadacitinib	Rinvoq	Teriparatide	Sondelbay	Sarilumab	Kevzara
Ustekinumab	Stelara	Teriparatide	Movymia	Tilrakizumab	Ilumetri
Active Patients	1152	Tralokinumab	Adtralza	Teriparatide	Sondelbay
		Upadacitinib	Rinvoq	Teriparatide	Sun
		Ustekinumab	Stelara	Teriparatide	Terrosa
		Ustekinumab	Pyzchiva	Tralokinumab	Adtralza
		Ustekinumab	Wezenla	Upadacitinib	Rinvoq
		Active Patients	1316	Ustekinumab	Pyzchiva
				Ustekinumab	Stelara
				Ustekinumab	Steqeyma
				Ustekinumab	Wezenla
				Active Patients	1553

Lloyds

April 2023-March 2024

Abatacept	Orencia
Advate	Advate
Baricitinib	Olumiant
Galcanezumab	Emgality
Glatiramer Acetate	Copaxone
Guselkumab	Tremfya
Interferon Beta	Avonex
Interferon Beta	Extavia
Interferon Beta	Rebif
Secukinumab	Cosentyx
Tocilizumab	RoActemra
Active Patients	445

April 2024-March 2025

Abatacept	Orencia
Baricitinib	Olumiant
Diroximel Fumarate	Vumerity
Erenumab	Aimovig
Galcanezumab	Emgality
Glatiramer Acetate	Copaxone
Guselkumab	Tremfya
Interferon Beta	Avonex
Interferon Beta	Extavia
Interferon Beta	Rebif
Ozanimod	Zeposia
Secukinumab	Cosentyx
Tocilizumab	RoActemra
Tralokinumab	Adtralza
Active Patients	407

April 2025-March 2026

Abatacept	Orencia
Baricitinib	Olumiant
Diroximel Fumarate	Vumerity
Erenumab	Aimovig
Galcanezumab	Emgality
Glatiramer Acetate	Copaxone
Guselkumab	Tremfya
Interferon Beta	Avonex
Interferon Beta	Rebif
Ozanimod	Zeposia
Secukinumab	Cosentyx
Tocilizumab	RoActemra
Active Patients	412

Personal Homecare Pharmacy

April 2023-March 2024
Adalimumab Yuflyma
Active Patients 414

April 2024-March 2025
Adalimumab Yuflyma
Active Patients 691

April 2025-March 2026
Adalimumab Yuflyma
Nemolizumab Nemludio
Active Patients 819

Pharmaxo

April 2023-March 2024

Certolizumab Pegol	Cimzia
Glatiramer Acetate	Copaxone
Romosozumab	Evenity
Active Patients	41

April 2024-March 2025

Certolizumab Pegol	Cimzia
Glatiramer Acetate	Copaxone
Romosozumab	Evenity
Active Patients	73

April 2025-March 2026

Certolizumab Pegol	Cimzia
Glatiramer Acetate	Copaxone
Romosozumab	Evenity
Active Patients	136